FOLH1 and prostate carcinoma: Positron emission tomography/computed tomography (PET/CT) addressing prostate-specific membrane antigen (PSMA) has been established in the last decade and is gaining relevance in the diagnostics and therapy of prostate cancer [11,12,13,14].